Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NSAID Panel Highlights Challenge Of Getting Comparative Safety Claim

Executive Summary

Does wide public health concern warrant flexibility in regulatory standards for safety claims? Advisory panel on cardiovascular risk of NSAIDs spotlights dual challenge of accurately determining drug risks and communicating risks in informative way.


Related Content

Pradaxa Medicare Study: Observing a Slow Attitude Change at FDA on Observational Studies
NSAID Safety Review: FDA Panel Seeks Continued PRECISION From Pfizer
NSAID Panel Could Give Naproxen Labeling Edge
FDA Replaces Avandia REMS Distribution Restrictions With Prescriber Training
Celebrex, NSAID Labeling Must Include Skin Reactions Warning, FDA Says
Vioxx Withdrawal Could Have Impact On Post-Marketing Surveillance Methods


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts